KalVista (KALV) CEO Sells $193,065 in Company Stock
Published on 4/20/2026
AI Summary
KalVista Pharmaceuticals' CEO, Benjamin Palleiko, sold $193,065 worth of company stock. This transaction may raise concerns among investors regarding the CEO's confidence in the company's future prospects. The stock sale's timing and implications for shareholder value can affect market perceptions. Monitoring such insider transactions can provide insights into future price movements for KalVista (KALV).
Related News
Markets
Sell Indonesia: Trading Desks React to Prabowo's Increased Influence
Jun 5
Markets
Asia Stocks Decline; Nikkei, KOSPI Drop Due to Tech Losses
Jun 5
Markets
SpaceX Not Approved for Early S&P 500 Entry Amid Policy Retention
Jun 5
Markets
SpaceX (SPACEX) faces S&P index entry setback after $4.94B loss
Jun 5